Leadership
Aisa Pharma’s leadership team combines extensive experience in drug development, clinical research, and company building in rare and autoimmune diseases. The team has led programs from preclinical proofofconcept through latestage clinical trials, regulatory interactions, and commercialization at both emerging and established biopharmaceutical companies.
Senior Leadership Team
Our senior leadership brings deep expertise across clinical development, medical affairs, regulatory, CMC, and business development, enabling integrated execution of our programs.
Andrew Sternlicht MD, MA
CEO and Founder
Andrew is board-certified anesthesiologist and businessman with 26 years of drug development experience at The Medicines Company, ActivBiotics and Dyax, and helped lead the development of an IV calcium channel blocker, Cleviprex®, as well as the development of Kalbitor®, a rare disease drug. Andrew has 10 patents and Aisa grew out of a personal need to find a treatment for his own Raynaud’s. On the faculty at Tufts Medical Center, Andrew received his BA and MA from Penn, his MD at Yale, and did postgraduate and residency training at Columbia, Harvard, and Cornell. In 1999 he started his first company, a health care services company called Hotelrecovery, Inc. He has been to both the FDA and Health Canada in different development programs. AISA’s origin came from a device he invented to keep patients warm during surgery as well as being the PI studies on N type calcium channel blocker treatments for certain pain conditions.
Angela Hansen, BsC
SVP Regulatory Affairs
Angela has over two decades of senior-level experience in pharmaceutical drug development and regulatory affairs, and brings a strategic and multidisciplinary approach to advancing global health initiatives. Her expertise spans integrated drug development, regulatory strategy, nonclinical and clinical program management, and cross-functional collaboration. She has led regulatory submissions across major health authorities including FDA, EMA, and Health Canada, and has authored key documents supporting INDs, NDAs, BLAs, CTAs, and MAAs. Her work is grounded in a deep understanding of GXP and ICH guidelines, and she is committed to innovative, compliant, and patient-focused drug development.
Meredith Todd
SVP Clinical Operations and President, AISA Pty Ltd (Australia)
Meredith is an accomplished pharmaceutical executive with 30 years of drug development expertise and a proven history of leading global cross-functional teams in the development and commercialization of acute hospital products. With previous experience at The Medicines Company and Novartis, she is skilled at strategy development, business planning and motivating teams under a unified strategic vision. Goal oriented and innovative professional with demonstrated leadership, decision making and problem-solving capability.
Gideon Shapiro, PhD
SVP Manufacturing and CMC
Gideon is a medicinal chemist by training and started his 35-year career in big pharma at Sandoz-Novartis in Basel, Switzerland where he advanced in management of the CNS Alzheimer’s group department. He then began CNS drug activities as VP of chemistry at Forum Pharmaceuticals and as CSO of Rugen. He has been successful in inventing and advancing novel therapeutics through the early drug discovery and development process from compound optimization through IND and clinical development. Gideon is also co-founder and CSO of Miralinc Pharma which is advancing a drug towards clinical trials in peripheral neuropathies and CMT hereditary.
Tim Cunningham
CFO
Tim has more than 30 years of experience leading finance and operations for life science and technology companies, including scale-up and guidance through transformative corporate growth events. He has raised >$500M in public and private equity and debt financing and led a $92M IPO.
